Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates

Bioconjugate Chemistry

Volumn 28, Issue 5, 2017, Pages 1371-1381

  Sun, Xiuxia ^a,b   Ponte, Jose F ^a   Yoder, Nicholas C ^a   Laleau, Rassol ^a   Coccia, Jennifer ^a,c   Lanieri, Leanne ^a   Qiu, Qifeng ^a   Wu, Rui ^a   Hong, Erica ^a,e   Bogalhas, Megan ^a   Wang, Lintao ^a   Dong, Ling ^a   Setiady, Yulius ^a   Maloney, Erin K ^a   Ab, Olga ^a   Zhang, Xiaoyan ^a,f   Pinkas, Jan ^a   Keating, Thomas A ^a   Chari, Ravi ^a   Erickson, Hans K ^a,d   Lambert, John M ^a   more..

^a IMMUNOGEN INC   (United States)

^b SHIRE   (United States)

^c REGENERON PHARMACEUTICALS INC   (United States)

^d GENENTECH INC   (United States)

^e LLP   (United States)

^f SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODIES; PHARMACOKINETICS;

ANTIBODY-DRUG CONJUGATES; BIODISTRIBUTIONS; CYTOTOXIC; CYTOTOXIC AGENTS; IN-VIVO; LYSINE RESIDUES; MICROTUBULES; PROPERTY; REGULATORY APPROVALS; TRASTUZUMAB;

AMINO ACIDS;

ANTIBODY DRUG CONJUGATE; EPIDERMAL GROWTH FACTOR RECEPTOR; FOLATE RECEPTOR 1; J 2898A; J 2898A N SUCCINIMIDYL 4 (N MALEIMIDOMETHYL)CYCLOHEXANE 1 CARBOXYLATE DM1 ANTIBODY DRUG CONJUGATE; MIRVETUXIMAB; MIRVETUXIMAB N SUCCINIMIDYL 4 (2 PYRIDYLDITHIO) 2 SULFOBUTANOATE DM4 ANTIBODY DRUG CONJUGATE; MONOCLONAL ANTIBODY; SOYBEAN TRYPSIN INHIBITOR N SUCCINIMIDYL 4 (N MALEIMIDOMETHYL)CYCLOHEXANE 1 CARBOXYLATE DM1 ANTIBODY DRUG CONJUGATE; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; MAYTANSINE;

ANALYTICAL PARAMETERS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLEARANCE; CONTROLLED STUDY; CYTOTOXICITY; DISULFIDE BOND; DRUG ACCUMULATION; DRUG ANTIBODY RATIO; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG STABILITY; DRUG TARGETING; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIVER; MOUSE; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TUMOR XENOGRAFT; ANIMAL; DRUG SCREENING; IMMUNOLOGY; KB CELL LINE; TISSUE DISTRIBUTION; TUMOR CELL CULTURE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEMALE; HUMANS; IMMUNOCONJUGATES; KB CELLS; MAYTANSINE; MICE; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85019636026     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/acs.bioconjchem.7b00062     Document Type: Article

References (26)

1. Lambert, J. M. and Chari, R. V. (2014) Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer J. Med. Chem. 57, 6949-64 10.1021/jm500766w
2. Senter, P. D. and Sievers, E. L. (2012) The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma Nat. Biotechnol. 30, 631-7 10.1038/nbt.2289
3. Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., and Zabinski, R. F. et al. 2004, Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate Clin. Cancer Res. 10, 7063-70 10.1158/1078-0432.CCR-04-0789
4. Catcott, K. C., McShea, M. A., Bialucha, C. U., Miller, K. L., Hicks, S. W., Saxena, P., Gesner, T. G., Woldegiorgis, M., Lewis, M. E., and Bai, C. et al. 2016, Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates mAbs 8, 513-23 10.1080/19420862.2015.1134408
5. King, H. D., Dubowchik, G. M., Mastalerz, H., Willner, D., Hofstead, S. J., Firestone, R. A., Lasch, S. J., and Trail, P. A. (2002) Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains J. Med. Chem. 45, 4336-43 10.1021/jm020149g
6. Lyon, R. P., Bovee, T. D., Doronina, S. O., Burke, P. J., Hunter, J. H., Neff-LaFord, H. D., Jonas, M., Anderson, M. E., Setter, J. R., and Senter, P. D. (2015) Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index Nat. Biotechnol. 33, 733-5 10.1038/nbt.3212
7. Yurkovetskiy, A. V., Yin, M., Bodyak, N., Stevenson, C. A., Thomas, J. D., Hammond, C. E., Qin, L., Zhu, B., Gumerov, D. R., and Ter-Ovanesyan, E. et al. 2015, A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy Cancer Res. 75, 3365-72 10.1158/0008-5472.CAN-15-0129
8. Ab, O., Whiteman, K. R., Bartle, L. M., Sun, X., Singh, R., Tavares, D., LaBelle, A., Payne, G., Lutz, R. J., and Pinkas, J., et al., (2015) IMGN853, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate, exhibits potent targeted anti-tumor activity against FRalpha-expressing tumors. Mol. Cancer Ther.. 14, 1605 10.1158/1535-7163.MCT-14-1095
9. Singh, R. and Erickson, H. K. (2009) Antibody-cytotoxic agent conjugates: preparation and characterization Methods Mol. Biol. 525, 445-67 xiv. 10.1007/978-1-59745-554-1-23
10. Goldmacher, V. S., Amphlett, G., Wang, L., and Lazar, A. C. (2015) Statistics of the Distribution of the Abundance of Molecules with Various Drug Loads in Maytansinoid Antibody-Drug Conjugates. Mol. Pharmaceutics. 12, 1738 10.1021/mp5007536
11. Kovtun, Y. V. and Goldmacher, V. S. (2007) Cell killing by antibody-drug conjugates Cancer Lett. 255, 232-40 10.1016/j.canlet.2007.04.010
12. Erickson, H. K., Park, P. U., Widdison, W. C., Kovtun, Y. V., Garrett, L. M., Hoffman, K., Lutz, R. J., Goldmacher, V. S., and Blattler, W. A. (2006) Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing Cancer Res. 66, 4426-33
13. Erickson, H. K., Widdison, W. C., Mayo, M. F., Whiteman, K., Audette, C., Wilhelm, S. D., and Singh, R. (2010) Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates Bioconjugate Chem. 21, 84-92 10.1021/bc900315y
14. Xie, H., Audette, C., Hoffee, M., Lambert, J. M., and Blattler, W. A. (2003) Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice J. Pharmacol. Exp. Ther. 308, 1073-1082 10.1124/jpet.103.060533
15. Okeley, N. M., Miyamoto, J. B., Zhang, X., Sanderson, R. J., Benjamin, D. R., Sievers, E. L., Senter, P. D., and Alley, S. C. (2010) Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate Clin. Cancer Res. 16, 888-97 10.1158/1078-0432.CCR-09-2069
16. Strop, P., Delaria, K., Foletti, D., Witt, J. M., Hasa-Moreno, A., Poulsen, K., Casas, M. G., Dorywalska, M., Farias, S., and Pios, A. et al. 2015, Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading Nat. Biotechnol. 33, 694-6 10.1038/nbt.3274
17. Wang, L., Amphlett, G., Blattler, W. A., Lambert, J. M., and Zhang, W. (2005) Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry Protein Sci. 14, 2436-46 10.1110/ps.051478705
18. Kim, M. T., Chen, Y., Marhoul, J., and Jacobson, F. (2014) Statistical modeling of the drug load distribution on trastuzumab emtansine (Kadcyla), a lysine-linked antibody drug conjugate Bioconjugate Chem. 25, 1223-32 10.1021/bc5000109
19. de Goeij, B. E. and Lambert, J. M. (2016) New developments for antibody-drug conjugate-based therapeutic approaches Curr. Opin. Immunol. 40, 14-23 10.1016/j.coi.2016.02.008
20. Vasalou, C., Helmlinger, G., and Gomes, B. (2015) A mechanistic tumor penetration model to guide antibody drug conjugate design PLoS One 10, e0118977 10.1371/journal.pone.0118977
21. Cilliers, C., Guo, H., Liao, J., Christodolu, N., and Thurber, G. M. (2016) Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy AAPS J. 18, 1117-30 10.1208/s12248-016-9940-z
22. Zhao, R. Y., Wilhelm, S. D., Audette, C., Jones, G., Leece, B. A., Lazar, A. C., Goldmacher, V. S., Singh, R., Kovtun, Y., and Widdison, W. C. et al. 2011, Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates J. Med. Chem. 54, 3606-23 10.1021/jm2002958
23. Lazar, A. C., Wang, L., Blattler, W. A., Amphlett, G., Lambert, J. M., and Zhang, W. (2005) Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry Rapid Commun. Mass Spectrom. 19, 1806-14 10.1002/rcm.1987
24. Ponte, J. F., Sun, X., Yoder, N. C., Fishkin, N., Laleau, R., Coccia, J., Lanieri, L., Bogalhas, M., Wang, L., and Wilhelm, S. et al. 2016, Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates Bioconjugate Chem. 27, 1588-98 10.1021/acs.bioconjchem.6b00117
25. Tomayko, M. M. and Reynolds, C. P. (1989) Determination of subcutaneous tumor size in athymic (nude) mice Cancer Chemother. Pharmacol. 24, 148-54 10.1007/BF00300234
26. Bissery, M. C., Guenard, D., Gueritte-Voegelein, F., and Lavelle, F. (1991) Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue Cancer Res. 51, 4845-52